Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Keytruda plus Lenvima is an option for advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-based chemo in any setting ...

so far as it is the only regimen so far with long-term survival data (48 months-plus) in patients with a poorer prognosis. Approval of the Keytruda-Lenvima regimen would be a win-win for Merck ...

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

ByInvesting.com • 01 Jun 2023 Merck Reports KEYTRUDA Plus LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...